Vasoactive Peptides in Portal Pressure

This study is currently recruiting participants.

Verified by Bayside Health, September 2005

Sponsored by:	Bayside Health
Information provided by:	Bayside Health
ClinicalTrials.gov Identifier:	NCT00163982

Purpose

This study is looking at the detection of vasoactive peptides in portal hypertension.

Condition	Intervention
Portal Hypertension	Drug: Norfloxacin

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Norfloxacin

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00163982

Contacts

Contact: William W Kemp, MBBS, FRACP

92762000 ext 3327

Locations

Australia, Victoria
Alfred Hospital	Recruiting
Melbourne, Victoria, Australia, 3181
Contact: William W Kemp, MBBS, FRACP 92762000 ext 3327 w.kemp@alfred.org.au

Sponsors and Collaborators

Bayside Health

Investigators

Principal Investigator:

William W Kemp, MBBS, FRACP

The Alfred

More Information

Study ID Numbers:	AH4204
Study First Received:	September 13, 2005
Last Updated:	July 25, 2007
ClinicalTrials.gov Identifier:	NCT00163982
Health Authority:	Australia: Human Research Ethics Committee

Keywords provided by Bayside Health:

HVPG > 12 mmHg

Study placed in the following topic categories:

Norfloxacin
Liver Diseases
Digestive System Diseases
Vascular Diseases

Hypertension, Portal
Portal hypertension
Hypertension

Additional relevant MeSH terms:

Anti-Infective Agents
Anti-Bacterial Agents
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses

Enzyme Inhibitors
Cardiovascular Diseases
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009